Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD7503 · 1 trial · 4 indications
To assess adverse events as a variable of safety and tolerability of AZD7503 following SC single dose administration.
| Arm | Type | Description |
|---|---|---|
| Cohort 1: AZD7503 dose 1 | EXPERIMENTAL | Randomised healthy participants will receive a single dose 1 of AZD7503. |
| Cohort 2: AZD7503 dose 2 | EXPERIMENTAL | Randomised healthy participants will receive a single dose 2 of AZD7503. |
| Cohort 3: AZD7503 dose 3 | EXPERIMENTAL | Randomised healthy participants will receive a single dose 3 of AZD7503. |
| Cohort 4: AZD7503 dose 4 | EXPERIMENTAL | Randomised healthy participants will receive a single dose 4 of AZD7503. |
| Cohort 5 : AZD7503 dose X | EXPERIMENTAL | Randomised healthy participants will receive a single dose X of AZD7503. |
| Cohort 6: AZD7503 dose Y | EXPERIMENTAL | Randomised healthy participants will receive a single dose Y of AZD7503. |
| Pooled Placebo for AZD7503 (Cohorts 1 to 6) | PLACEBO_COMPARATOR | Randomised healthy participants will receive placebo. |
| Japanese Cohort 1: AZD7503 dose 3 | EXPERIMENTAL | Randomised healthy Japanese participants will receive a single dose 3 of AZD7503. |
| Japanese Cohort 2: AZD7503 dose 4 | EXPERIMENTAL | Randomised healthy Japanese participants will receive a single dose 4 of AZD7503. |
| Placebo (Japanese Cohorts) | PLACEBO_COMPARATOR | Randomised healthy Japanese participants will receive placebo. |
| Chinese Cohort: AZD7503 dose 4 | EXPERIMENTAL | Randomised healthy Chinese participants will receive a single dose 4 of AZD7503. |
| Placebo (Chinese Cohort) | PLACEBO_COMPARATOR | Randomised healthy Chinese participants will receive placebo. |
| Name | Type | Description |
|---|---|---|
| AZD7503 | DRUG | Randomised participants will receive a single ascending dose of AZD7503 by SC injection (dose 1, dose 2, dose 3, dose 4, dose X and dose Y). |
| Placebo | DRUG | Randomised participants will receive placebo by SC injection |
Inclusion Criteria: * Healthy non smoking male and/or female (of non childbearing potential) participants with suitable veins for cannulation or repeated venipuncture. * Females must have a negative pregnancy test at screening and on admission to the study centre, must not be lactating and must be ...
AZD7503 is an investigational small molecule developed by AstraZeneca PLC. It has been studied in a Phase 1 clinical trial in healthy adult participants, evaluating safety, tolerability, and pharmacokinetics. The specific disease indication for AZD7503 has not been publicly disclosed, and it remains in early clinical development.
AZD7503 is being developed by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. AstraZeneca sponsored the Phase 1 study of AZD7503 conducted in the United States. The compound is an investigational small molecule and has not been approved for any indication.
AZD7503 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The study enrolled 56 healthy participants and assessed safety, tolerability, and pharmacokinetics. AZD7503 is investigational and has not received FDA approval for any indication.
AZD7503 was evaluated in the Phase 1 trial NCT05143905, titled a study to assess the safety, tolerability and pharmacokinetics of AZD7503 in healthy participants. The trial was completed, enrolled 56 participants in the United States, and used a randomized, double-blind, placebo-controlled design with healthy volunteers.
The AZD7503 Phase 1 trial NCT05143905 was a randomized, double-blind, placebo-controlled study in healthy adult participants aged 18 years and older. It enrolled 56 participants across sites in the United States and evaluated safety, tolerability, and pharmacokinetics. The study has been completed.